- Home
- KLRS vs CUE Comparison
KLRS vs CUE Comparison
Compare KLRS & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KLRS
- CUE
- Stock Information
- Founded
- KLRS 2019
- CUE 2014
- Country
- KLRS United States
- CUE United States
- Employees
- KLRS N/A
- CUE N/A
- Industry
- KLRS Biotechnology: Biological Products (No Diagnostic Substances)
- CUE Biotechnology: Pharmaceutical Preparations
- Sector
- KLRS Health Care
- CUE Health Care
- Exchange
- KLRS Nasdaq
- CUE Nasdaq
- Market Cap
- KLRS 57.5M
- CUE 60.6M
- IPO Year
- KLRS N/A
- CUE 2018
- Fundamental
- Price
- KLRS $8.60
- CUE $0.92
- Analyst Decision
- KLRS
- CUE Strong Buy
- Analyst Count
- KLRS 0
- CUE 4
- Target Price
- KLRS N/A
- CUE $4.75
- AVG Volume (30 Days)
- KLRS 20.9K
- CUE 154.3K
- Earning Date
- KLRS 05-15-2025
- CUE 05-08-2025
- Dividend Yield
- KLRS N/A
- CUE N/A
- EPS Growth
- KLRS N/A
- CUE N/A
- EPS
- KLRS N/A
- CUE N/A
- Revenue
- KLRS N/A
- CUE $9,532,000.00
- Revenue This Year
- KLRS N/A
- CUE $73.11
- Revenue Next Year
- KLRS N/A
- CUE $11.02
- P/E Ratio
- KLRS N/A
- CUE N/A
- Revenue Growth
- KLRS N/A
- CUE 149.53
- 52 Week Low
- KLRS $7.96
- CUE $0.45
- 52 Week High
- KLRS $24.15
- CUE $2.26
- Technical
- Relative Strength Index (RSI)
- KLRS N/A
- CUE 33.15
- Support Level
- KLRS N/A
- CUE $0.95
- Resistance Level
- KLRS N/A
- CUE $1.03
- Average True Range (ATR)
- KLRS 0.00
- CUE 0.08
- MACD
- KLRS 0.00
- CUE 0.01
- Stochastic Oscillator
- KLRS 0.00
- CUE 3.85
Stock Price Comparison Chart: KLRS vs CUE
■ KLRS
■ CUE
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.
Share on Social Networks:
0